Wockhardt Cited by FDA for Quality Control Failures - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Wockhardt Cited by FDA for Quality Control Failures


FDA has posted a Form 483 issued in March 2014 to Wockhardt’s Morton Grove Pharmaceuticals facility. Detailed in the FDA-483 are a variety of quality control, GMP, and sanitation issues observed during an investigation conducted from January to March 2014. Observations included using chromatography testing and stability monitoring procedures for which the company previously received FDA warning letters at two other plants.  Specifically, the company has been using “trial” injections during chromatography testing without proper documentation procedures.

The FDA-483 also noted the company had not properly followed stability testing programs and had failed to properly review batch discrepancies and document out-of-specification investigations. To further the quality problems noted, the FDA investigator stated that the quality control unit did not fully investigate errors, and operating procedures were not properly updated when changes occurred.

The company was also cited for failure to maintain clean and sanitary conditions, including observations of mold and improperly sanitized equipment. The FDA inspector also cited improper personnel gowning and health habits.

Source: FDA.gov

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here